title: Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.
abstract: To assess the changes in estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 expression in breast cancer patients after various neoadjuvant chemotherapies. Data from 138 locally advanced breast cancer patients with histological diagnoses were reviewed. Seventy patients (group 1) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 50 mg/m(2) pirarubicin every 21 days. Sixty-eight patients (group 2) were given 4 cycles of 500 mg/m(2) cyclophosphamide and 75 mg/m(2) docetaxel every 21 days. The biomarker changes of the operated tumor tissues were compared with the initial core biopsies. ER, PR, HER2 and Ki-67 expression changed by 28.6%, 22.9%, 17.1% and 54.3%, respectively, after neoadjuvant chemotherapy in group 1 and 16.2%, 22.1%, 13.2% and 70.6%, respectively, after neoadjuvant chemotherapy in group 2. There were significant differences between the groups regarding ER and Ki-67 status changes, and these changes can be used to inform treatment strategies.
authors.affiliation: Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
authors.forename: Guangchao
authors.initials: G
authors.lastname: Jin
authors.affiliation: Intensive Care Unit, Shan Dong Province Hospital, Shandong University Jinan 250012, P.R. China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Han
authors.affiliation: Department of Ultrasound, Jinan Central Hospital, Shandong University Jinan 250012, P.R. China.
authors.forename: Cun
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
authors.forename: Liansheng
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Pathology, Jinan Central Hospital, Shandong University Jinan 250012, P.R. China.
authors.forename: Butong
authors.initials: B
authors.lastname: Ding
authors.affiliation: Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
authors.forename: Shijin
authors.initials: S
authors.lastname: Xuan
authors.affiliation: Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
authors.forename: Xianqiang
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
authors.forename: Guohui
authors.initials: G
authors.lastname: Ma
authors.affiliation: Department of Breast Surgery, Jinan Central Hospital, Shandong University Jinan 250021, P.R. China.
authors.forename: Jun
authors.initials: J
authors.lastname: Gao
authors.affiliation: Department of Breast Surgery, Shan Dong Province Hospital, Shandong University Jinan 250012, P.R. China.
authors.forename: Xingsong
authors.initials: X
authors.lastname: Tian
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D011960:Receptors, Estrogen / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D011980:Receptors, Progesterone / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D003520:Cyclophosphamide; D000077143:Docetaxel; D004317:Doxorubicin; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; C027260:pirarubicin; C508053:ERBB2 protein, human
keywords: Breast cancer; ER; HER2; Ki-67; PR; neoadjuvant chemotherapy